DCC4196 |
Pm00104 |
Potent anticancer tetrahydroisoquinoline alkaloid, being able to form a covalent bond with the amino group of a guanine in selected triplets of DNA duplexes and eventually give rise to double-strand breaks |
|
DCC4197 |
Pmed-1 |
Novel inhibitor of β-catenin signaling, significantly reduced β-catenin activity in hepatoblastoma and several HCC cells |
|
DCC4198 |
Pmmb-317 |
Novel potent irriversible dual inhibitor of tubulin and epidermal growth factor receptor (EGFR), inducing the apoptosis of A549 cells in a dose- and time-dependent manner, along with decrease in mitochondrial membrane potential (MMP), production of ROS an |
|
DCC4199 |
Pmpmease-in L-23 |
Novel inhibitor of prenylated methylated protein methyl esterase (PMPMEase), a key enzyme in the reversible methylation/demethylation step in the protein prenylation pathway |
|
DCC4200 |
Pmpmease-in L-28 |
Novel inhibitor of prenylated methylated protein methyl esterase (PMPMEase), a key enzyme in the reversible methylation/demethylation step in the protein prenylation pathway |
|
DCC4201 |
P-mppf Dihydrochloride |
Selective 5-HT1A serotonin receptor antagonist |
|
DCC4202 |
P-nitro-pifithrin-α |
Cell-permeable analog of pifithrin-α, potently blocking p53-mediated expression of p21/WAF1 and apoptosis |
|
DCC4203 |
Pnr-4-20 |
Novel G Protein-Biased Cannabinoid 1 (CB1) Receptor Agonist |
|
DCC4204 |
Pnu-292137 |
Potent inhibitor of CDK2/cyclin A |
|
DCC4205 |
Pnu-69176e |
Allosteric modulator of 5-HT(2C)R with no intrinsic agonist activity |
|
DCC4206 |
Pnz-tmp |
The first small-molecule approach capable of detecting and controlling engineered cell-cell outputs |
|
DCC4207 |
Podoverine A |
Novel microtubule destabilizing natural product from the Podophyllum species |
|
DCC4208 |
Pol I Inhibitor T5 |
Novel RNA polymerase I inhibitor, targeting ribosomal DNA G-quadruplexes, potently and selectively inhibiting cell growth by high-affinity binding to G4s in ribosomal DNA, impairing RNA polymerase I (Pol I) elongation, inducing a rapid inhibition of Pol I |
|
DCC4209 |
Pol7001 |
Novel macrocycle antibiotic with selective and potent activity against P. aeruginosa |
|
DCC4210 |
Poloppin-ii |
Novel modulator of protein-protein interactions of the mitotic polo-like kinases, targeting KRAS mutant xenografts, indicate avenues, acting synergistically with Crizotinib, an inhibitor of the c-MET receptor, against mutant KRAS-expressing cancer cells |
|
DCC4211 |
Poloxipan |
Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis |
|
DCC4212 |
Poly(ethyleneimine) Solution |
Used for the transfection of a broad variety of cell lines; Antimicrobial; Novel binding agent of diffusive gradients in thin-films (DGT) technique (PEI-DGT) |
|
DCC4213 |
polygonatone D |
Novel activator of Adenosine monophosphate (AMP)-activated protein kinase (AMPK) |
|
DCC4214 |
Polymyxin |
Antibiotic as a last-line therapy to treat infections caused by these life-threatening 'superbugs' |
|
DCC4215 |
polyphenol 13b |
Novel pan-inhibitor of KCa3.1/KCa2 channels |
|
DCC4216 |
Pom2-c-hmbp |
Potent Activator of Vγ9Vδ2 T-Lymphocytes; HMBPP ananlog prodrug |
|
DCC4217 |
Ponfibrate |
Hypobetalipoproteinemic and Lipid decreasing agent |
|
DCC4218 |
Poziotinib Hydrochloride |
Novel pan-human EGF receptor (HER) inhibitor |
|
DCC4219 |
Ppa250 |
Novel iNOS homodimerization inhibitor |
|
DCC4220 |
Pparalpha/delta-in-11 |
The first reported PPARα/δ dual antagonist |
|
DCC4221 |
Pparalpha/gamma Agonist N15 |
Novel dual PPARα/γ agonist, ameliorating insulin resistance and gluconeogenesis in vivo and vitro |
|
DCC4222 |
Ppi Inhibitor-i |
Novel inhibitor of protein-protein interaction (PPI), blocking #212121; font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 14px; font-style: no |
|
DCC4223 |
pp-ii-a03 |
Novel insulin mimetic |
|
DCC4224 |
Ppi-in-3344 |
Novel pan-RAS-effector PPI inhibitor |
|
DCC4225 |
Ppk1-in-17 |
Novel PPK1 inhibitor, preventing UTI effectively through the disruption of the PPK1 function |
|